Skip to main content
Genomic Vision logo

Genomic Vision — Investor Relations & Filings

Ticker · GV ISIN · FR0011799907 LEI · 969500UXJNBY1C8Y8471 PA Professional, scientific and technical activities
Open in API
Filings indexed 412 across all filing types
Latest filing 2022-09-29 Earnings Release
Country FR France
Listing PA GV

About Genomic Vision

https://www.genomicvision.com/

Genomic Vision is a biotechnology company specializing in the direct visualization and analysis of single DNA molecules through its proprietary Molecular Combing technology. This platform provides highly accurate characterization of large-scale genomic modifications, offering critical insights into genetic integrity and stability. The company's primary focus is on providing quality control (QC) solutions for the bioproduction and cell and gene therapy markets, ensuring the safety and efficacy of advanced therapeutic products. In drug discovery, its Replication Combing Assay (RCA) is used to assess the effects of compounds on DNA replication. Genomic Vision's tools and services support the entire lifecycle of biopharmaceutical development, from research to production.

Recent filings

Filing Released Lang Actions
Inside Information / News release on accounts, results
Earnings Release Classification · 99% confidence The document explicitly announces the "FIRST-HALF 2022 RESULTS" and provides detailed financial tables comparing H1 2022 results (€511k revenue, €2.5 million operating loss) against H1 2021. It includes key financial metrics, operational commentary, and a section titled "Upcoming financial publication" mentioning the Q3 2022 revenue release date. This content structure is characteristic of an Earnings Release (ER), which provides the initial announcement of periodical financial results (key highlights). While it contains detailed figures, it is presented as a press release summarizing the period, rather than the comprehensive, audited report (10-K or IR). Since it covers a period shorter than a year (half-year), the most appropriate classification is Earnings Release (ER). It is not an Interim/Quarterly Report (IR) because IR typically implies the full, detailed report filing, whereas this reads like the initial press announcement. H1 2022
2022-09-29 English
Informations privilégiées / Communiqué sur comptes, résultats
Earnings Release Classification · 99% confidence The document explicitly states it is publishing the "RÉSULTATS SEMESTRIELS 2022" (Half-Year Results 2022) and provides detailed financial tables comparing H1 2022 results to H1 2021 results, including revenue, operating expenses, and net result, as of June 30, 2022. This content structure—a summary of financial performance for a period shorter than a year—is characteristic of an Interim/Quarterly Report. Although it mentions the full report is available online, the document itself contains the core financial highlights and management discussion, making it an Interim Report (IR) rather than just a publication announcement (RPA). H1 2022
2022-09-29 French
Franchissement de seuils
Major Shareholding Notification Classification · 99% confidence The document is titled "Déclaration de franchissement de seuils (article L. 233-7 du code de commerce)" and details that M. Bruno Chalom Sayada crossed ownership thresholds (5% of capital and voting rights) in GENOMIC VISION on September 21, 2022. This type of filing, reporting changes in significant share ownership by an individual or entity, directly corresponds to the definition of a Major Shareholding Notification. The French regulatory context (AMF reference) confirms this is a mandatory disclosure regarding shareholding changes, matching the criteria for code MRQ.
2022-09-23 French
Informations privilégiées / Autres communiqués
Capital/Financing Update Classification · 98% confidence The document announces that Genomic Vision has drawn the first tranche (€2M) of a financing program structured as convertible bonds with stock warrants (OCABSA) from Winance. This action involves the issuance of debt instruments convertible into equity, which directly relates to the company's capital structure and fundraising activities. This fits the definition of 'Capital/Financing Update' (CAP). It is not a full annual report (10-K), an earnings release (ER), or a simple dividend notice (DIV). Since it is a detailed announcement of a specific financing event, CAP is the most appropriate classification, rather than the general 'Regulatory Filing' (RNS). The document length is substantial enough (6623 chars) that it is the primary announcement, not just a notice of publication (RPA).
2022-09-06 French
Inside Information / Other news releases
Capital/Financing Update Classification · 99% confidence The document is a press release announcing a specific corporate financial action: the issuance of the first tranche of convertible notes with warrants (OCABSA) for €2 million, as part of a larger financing line with Winance. This action directly relates to the company's capital structure and fundraising activities. Based on the definitions, the category 'Capital/Financing Update' (CAP) is the most appropriate classification for announcements detailing fundraising, financing activities, or capital structure changes.
2022-09-06 English
Informations privilégiées / Autres communiqués
Earnings Release Classification · 95% confidence The document is a press release from Genomic Vision titled 'Information financière du 1er semestre 2022'. It provides key financial highlights (revenue, cash position) for the first half of the year, but explicitly states that the full 'Résultats semestriels 2022' will be published later (September 29, 2022). Since this is an initial announcement of financial results containing key highlights rather than the full comprehensive interim report, it falls under the Earnings Release (ER) category. H1 2022
2022-07-22 French

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.